• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New osteoporosis therapy’s dual effects on bone tissue

Bioengineer by Bioengineer
June 25, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Dr. Pascale Chavassieux

Sclerostin is a protein produced by osteocytes in the bone that inhibits bone formation. A recent analysis of results from a clinical trial reveals the beneficial effects of romosozumab, an antibody therapy that targets sclerostin, on bone tissue in postmenopausal women with osteoporosis. The findings are published in the Journal of Bone and Mineral Research.

Romosozumab increases serum markers of bone formation and decreases those of bone breakdown, or resorption. This is associated with an increased bone mineral density and a reduced risk of bone fractures.

This latest analysis included 107 patients with osteoporosis who were enrolled in the multicenter, phase 3 clinical trial called the Fracture Study in Postmenopausal Women with Osteoporosis (FRAME) study and who underwent bone biopsies. The analysis showed that at the tissue level, romosozumab produced an early and transient increase in bone formation and a persistent decrease in bone resorption. This led to significant increases in bone mass and improved bone microarchitecture (Figure) after 12 months of therapy. These effects contribute to the reduced fracture risk previously reported in postmenopausal women with osteoporosis treated with romosozumab.

“Romosozumab is the first osteoporosis therapy with a dual effect on bone tissue, increasing bone formation and decreasing resorption” said lead author Dr. Pascale Chavassieux, of the University of Lyon, in France.

###

Media Contact
Penny Smith
newsroom@wiley.com

Related Journal Article

http://dx.doi.org/10.1002/jbmr.3735

Tags: Medicine/HealthMusculatureOrthopedic MedicinePublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Interleukin Biomarkers Show Varied Links to Outcomes After Acute Brain Injury

Interleukin Biomarkers Show Varied Links to Outcomes After Acute Brain Injury

November 19, 2026
Youth Archery Review Finds Inconclusive Evidence For Lasting Cognitive Benefits

Youth Archery Review Finds Inconclusive Evidence For Lasting Cognitive Benefits

November 19, 2026

Cross-Sectional Study Identifies Knowledge Gaps and Practice Predictors in Obstructive Sleep Apnea

November 19, 2026

Transient Retinal Infiltrates in Behçet Uveitis Frequently Mimic Infectious Disease

November 19, 2026
Please login to join discussion

POPULAR NEWS

  • Single-Cell Study Links SLC2A1-Driven Metabolism to Immune Evasion in Cholangiocarcinoma

    Single-Cell Study Links SLC2A1-Driven Metabolism to Immune Evasion in Cholangiocarcinoma

    29 shares
    Share 12 Tweet 7
  • Deubiquitinase DUB3 Stabilizes GCase and Reduces Neurodegeneration in Parkinson’s Disease Models

    29 shares
    Share 12 Tweet 7
  • HPV16 and HPV18 Infection Associated With High-Grade Cervical Lesions in Study

    29 shares
    Share 12 Tweet 7
  • Southeast Asian Wildlife Disease Surveillance Relies Predominantly on Passive Outbreak Tracking

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Interleukin Biomarkers Show Varied Links to Outcomes After Acute Brain Injury

Youth Archery Review Finds Inconclusive Evidence For Lasting Cognitive Benefits

Salvianolic Acid C Blocks Influenza Virus Release by Targeting Viral Neuraminidase

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.